| Product Code: ETC088665 | Publication Date: Jun 2021 | Updated Date: Aug 2025 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The radiopharmaceuticals market size in Malaysia was valued at around US$ 7 Million by 2025 with significant growth opportunities driven by rising geriatric population along with expanding healthcare infrastructure leading to higher spending on therapeutics solutions In addition favorable insurance policies coupled with emergence of sophisticated diagnostics techniques such as Positron Emission Tomography (PET) scan systems which use radiopharmaceuticals drugs would further support increase adoption rate Additionally rapid development within nuclear medicine field along with launch of innovative products has enabled better diagnosis accuracy while improving patient outcomes Besides rising incidence rates associated cancer diseases could also boost segmental revenue contribution Further strategic collaborations between governments medical organizations vendors manufacturers regarding radioisotope production may lead create lucrative business avenues over coming years
The Malaysia radiopharmaceutical market is expected to see positive growth due to advancements in medical imaging and diagnostics. Radiopharmaceuticals are essential in nuclear medicine, used for diagnostic imaging and targeted therapies in various medical conditions. As Malaysia healthcare infrastructure improves and the demand for accurate and early disease detection rises, the market for radiopharmaceuticals is likely to expand.
In the radiopharmaceutical market, challenges arise from strict regulatory requirements and the need for extensive research and development to produce safe and effective radiopharmaceuticals. Manufacturers need to navigate regulatory approvals and invest in research to expand their radiopharmaceutical offerings.
The radiopharmaceutical market in Malaysia faced challenges as healthcare resources were redirected to combat the pandemic. Reduced elective medical procedures and imaging studies impacted the demand for radiopharmaceuticals. Supply chain disruptions and logistic constraints affected product availability.
The radiopharmaceutical market in Malaysia is served by companies specializing in the production and distribution of radiopharmaceuticals used in medical imaging and nuclear medicine. Key players in Malaysia radiopharmaceutical market may include RadioPharmaTech Sdn Bhd, MedImaging Solutions, and PharmaRadio Products. These companies are likely to focus on regulatory compliance, product safety, and providing reliable radiopharmaceuticals to support medical diagnoses and treatments.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Malaysia Radiopharmaceutical Market Overview |
3.1 Malaysia Country Macro Economic Indicators |
3.2 Malaysia Radiopharmaceutical Market Revenues & Volume, 2021 & 2031F |
3.3 Malaysia Radiopharmaceutical Market - Industry Life Cycle |
3.4 Malaysia Radiopharmaceutical Market - Porter's Five Forces |
3.5 Malaysia Radiopharmaceutical Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.6 Malaysia Radiopharmaceutical Market Revenues & Volume Share, By Applications, 2021 & 2031F |
3.7 Malaysia Radiopharmaceutical Market Revenues & Volume Share, By Procedural Volume Assessment, 2021 & 2031F |
3.8 Malaysia Radiopharmaceutical Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.9 Malaysia Radiopharmaceutical Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 Malaysia Radiopharmaceutical Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer and cardiovascular diseases in Malaysia |
4.2.2 Growing investments in healthcare infrastructure and facilities |
4.2.3 Rising adoption of nuclear medicine for diagnostic and therapeutic purposes |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval and use of radiopharmaceuticals |
4.3.2 High costs associated with the production and procurement of radiopharmaceuticals |
4.3.3 Limited availability of skilled professionals in the field of nuclear medicine |
5 Malaysia Radiopharmaceutical Market Trends |
6 Malaysia Radiopharmaceutical Market, By Types |
6.1 Malaysia Radiopharmaceutical Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 Malaysia Radiopharmaceutical Market Revenues & Volume, By Types, 2021-2031F |
6.1.3 Malaysia Radiopharmaceutical Market Revenues & Volume, By Diagnostic Nuclear Medicine, 2021-2031F |
6.1.4 Malaysia Radiopharmaceutical Market Revenues & Volume, By Therapeutic Nuclear Medicine, 2021-2031F |
6.2 Malaysia Radiopharmaceutical Market, By Applications |
6.2.1 Overview and Analysis |
6.2.2 Malaysia Radiopharmaceutical Market Revenues & Volume, By Diagnostic Applications, 2021-2031F |
6.2.3 Malaysia Radiopharmaceutical Market Revenues & Volume, By Therapeutic Applications, 2021-2031F |
6.3 Malaysia Radiopharmaceutical Market, By Procedural Volume Assessment |
6.3.1 Overview and Analysis |
6.3.2 Malaysia Radiopharmaceutical Market Revenues & Volume, By Diagnostic Procedures, 2021-2031F |
6.3.3 Malaysia Radiopharmaceutical Market Revenues & Volume, By Therapeutic Procedures, 2021-2031F |
6.4 Malaysia Radiopharmaceutical Market, By Source |
6.4.1 Overview and Analysis |
6.4.2 Malaysia Radiopharmaceutical Market Revenues & Volume, By Nuclear Reactors, 2021-2031F |
6.4.3 Malaysia Radiopharmaceutical Market Revenues & Volume, By Cyclotrons, 2021-2031F |
6.5 Malaysia Radiopharmaceutical Market, By End-users |
6.5.1 Overview and Analysis |
6.5.2 Malaysia Radiopharmaceutical Market Revenues & Volume, By Hospitals, 2021-2031F |
6.5.3 Malaysia Radiopharmaceutical Market Revenues & Volume, By Ambulatory Surgical Centers, 2021-2031F |
6.5.4 Malaysia Radiopharmaceutical Market Revenues & Volume, By Diagnostic Centers, 2021-2031F |
6.5.5 Malaysia Radiopharmaceutical Market Revenues & Volume, By Cancer Research Institutes, 2021-2031F |
6.5.6 Malaysia Radiopharmaceutical Market Revenues & Volume, By Others, 2021-2031F |
7 Malaysia Radiopharmaceutical Market Import-Export Trade Statistics |
7.1 Malaysia Radiopharmaceutical Market Export to Major Countries |
7.2 Malaysia Radiopharmaceutical Market Imports from Major Countries |
8 Malaysia Radiopharmaceutical Market Key Performance Indicators |
8.1 Number of new cancer and cardiovascular disease cases diagnosed annually |
8.2 Investment in research and development of new radiopharmaceutical products |
8.3 Number of nuclear medicine facilities and imaging centers in Malaysia |
9 Malaysia Radiopharmaceutical Market - Opportunity Assessment |
9.1 Malaysia Radiopharmaceutical Market Opportunity Assessment, By Types, 2021 & 2031F |
9.2 Malaysia Radiopharmaceutical Market Opportunity Assessment, By Applications, 2021 & 2031F |
9.3 Malaysia Radiopharmaceutical Market Opportunity Assessment, By Procedural Volume Assessment, 2021 & 2031F |
9.4 Malaysia Radiopharmaceutical Market Opportunity Assessment, By Source, 2021 & 2031F |
9.5 Malaysia Radiopharmaceutical Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 Malaysia Radiopharmaceutical Market - Competitive Landscape |
10.1 Malaysia Radiopharmaceutical Market Revenue Share, By Companies, 2024 |
10.2 Malaysia Radiopharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |